Abstract Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide
and a major economic burden. The prevalence of T2DM is rising, suggesting more effective …

Hypertension poses a significant burden in the general population, being responsible for
increasing cardiovascular morbidity and mortality, leading to adverse outcomes. Moreover …

Background The cardiovascular effects of adding once-weekly treatment with exenatide to
usual care in patients with type 2 diabetes are unknown. Methods We randomly assigned …

The incretin system has become an important target in the treatment of type 2 diabetes in
recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose …

A reliable, individualized, and dynamic surrogate of cardiovascular risk, synoptic for key
biologic mechanisms, could shorten the path for drug development, enhance drug cost …

Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin
secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety …

Background: Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart
failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering) …

Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce
events in patients with diabetes and cardiovascular (CV) disease, a group common in …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-
1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with …